🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

AmerisourceBergen, Merck to Expand Blockchain Test Project for Tracking Drugs

Published 06/08/2018, 06:25 AM
Updated 06/08/2018, 06:41 AM
 AmerisourceBergen, Merck to Expand Blockchain Test Project for Tracking Drugs
MRK
-
PFE
-
MCK
-
COR
-

US healthcare sector giants AmerisourceBergen (NYSE:ABC) and Merck (NYSE:MRK) & Co intend to expand a blockchain pilot that was concluded in 2017, the Wall Street Journal reports. During the test, the companies tracked the ownership of medicines along the supply chain route. The upcoming trial is expected to include more drugs and healthcare devices and carry out more elaborate transactions, according to AmerisourceBergen CIO Dale Danilewitz.

A blockchain implementation is preferred in light of current federal laws, which require of healthcare companies to ensure the drugs reach the intended recipient.

Danilewitz said the test would focus on the verification process for drugs that a hospital or retailer returns to the company. If the history of the drugs is clean, they could be resold.

“We’re making sure of the provenance of the product, guaranteeing it hasn’t been tampered with all the way through the chain to the patient. Blockchain is such a natural fit for that kind of capability,” he added.

Danilewitz revealed that Amerisource resells about 16 million product units each year, which is the equivalent of $3 billion in revenue. But if blockchain were to be implemented, that figure would go much higher. It is currently insignificant when measured against the company’s total revenue, which was $153.1 billion last year.

Blockchain seems to be highly relevant given that the healthcare industry is facing new regulations. They will come into force in 2019 and aim to detect and remove fake, stolen, or contaminated drugs. Under the current Drug Supply Chain Security Act of 2013, companies have to adopt an electronic system to trace specific prescription medications from manufacturers to healthcare providers, distributors, retailers, and patients.

AmerisourceBergen’s pilots are part of a broader initiative called MediLedger, on which we reported last year. Due to regulatory pressures, the company teamed up with Pfizer (NYSE:PFE) and McKesson (NYSE:MCK), among others, to explore the use of blockchain for tracking drugs.

The drug wholesale giant has applied blockchain solutions provided by SAP. On Thursday, we reported that SAP had made its blockchain-as-a-service solution available to all customers. AmerisourceBergen is also interested in the Hyperledger blockchain.


This article appeared first on Cryptovest

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.